{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:40:37Z","timestamp":1723563637560},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00393-024-01534-7","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T13:02:01Z","timestamp":1719493321000},"page":"447-454","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update Lupusnephritis","Update on lupus nephritis"],"prefix":"10.1007","volume":"83","author":[{"given":"M.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Chehab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"issue":"2","key":"1534_CR1","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/ijms25020805","volume":"25","author":"FK Alduraibi","year":"2024","unstructured":"Alduraibi\u00a0FK, Tsokos\u00a0GC (2024) Lupus nephritis biomarkers: a\u00a0critical review. Int J Mol Sci 25(2):805","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1534_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani\u00a0S, Meara\u00a0A, Rovin\u00a0BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12(5):825\u2013835","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1534_CR3","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1038\/s41598-017-06516-1","volume":"7","author":"JC Alml\u00f6f","year":"2017","unstructured":"Alml\u00f6f\u00a0JC, Alexsson\u00a0A, Imgenberg-Kreuz\u00a0J et\u00a0al (2017) Novel risk genes for systemic lupus erythematosus predicted by random forest classification. Sci Rep 7(1):6236","journal-title":"Sci Rep"},{"issue":"9","key":"1534_CR4","doi-asserted-by":"publisher","first-page":"e45356","DOI":"10.1371\/journal.pone.0045356","volume":"7","author":"E Alonso-Perez","year":"2012","unstructured":"Alonso-Perez\u00a0E, Suarez-Gestal\u00a0M, Calaza\u00a0M et\u00a0al (2012) European consortium of SLE DNA collections. Further evidence of subphenotype association with systemic lupus erythematosus susceptibility loci: a\u00a0European cases only study. PLoS One 7(9):e45356","journal-title":"PLoS One"},{"issue":"9","key":"1534_CR5","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer\u00a0M, Costenbader\u00a0K, Daikh\u00a0D et\u00a0al (2019) 2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151\u20131159","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1534_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00393-022-01214-4","volume":"83","author":"M Aringer","year":"2024","unstructured":"Aringer\u00a0M, Finzel\u00a0S, Voll\u00a0RE (2024) Immunpathogenese des systemischen Lupus erythematodes [Immunopathogenesis of systemic lupus erythematosus]. Z\u00a0Rheumatol 83(1):68\u201376","journal-title":"Z Rheumatol"},{"issue":"4","key":"1534_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema\u00a0IM, Wilhelmus\u00a0S, Alpers\u00a0CE et\u00a0al (2018) Revision of the international society of nephrology\/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int 93(4):789\u2013796","journal-title":"Kidney Int"},{"issue":"1","key":"1534_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/0961203318815577","volume":"28","author":"A Barnado","year":"2019","unstructured":"Barnado\u00a0A, Carroll\u00a0RJ, Casey\u00a0C, Wheless\u00a0L, Denny\u00a0JC, Crofford\u00a0LJ (2019) Phenome-wide association study identifies dsDNA as a\u00a0driver of major organ involvement in systemic lupus erythematosus. Lupus 28(1):66\u201376","journal-title":"Lupus"},{"key":"1534_CR9","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.21955","volume":"54","author":"S Bernatsky","year":"2006","unstructured":"Bernatsky\u00a0S, Boivin\u00a0JF, Joseph\u00a0L et\u00a0al (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550\u20132557","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1534_CR10","doi-asserted-by":"publisher","first-page":"e84450","DOI":"10.1371\/journal.pone.0084450","volume":"8","author":"K Bolin","year":"2013","unstructured":"Bolin\u00a0K, Sandling\u00a0JK, Zickert\u00a0A et\u00a0al (2013) Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One 8(12):e84450","journal-title":"PLoS One"},{"issue":"10","key":"1534_CR11","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/hmg\/ddaa030","volume":"29","author":"L Chen","year":"2020","unstructured":"Chen\u00a0L, Wang\u00a0YF, Liu\u00a0L et\u00a0al (2020) Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity. Hum Mol Genet 29(10):1745\u20131756","journal-title":"Hum Mol Genet"},{"key":"1534_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.03280807","volume":"3","author":"YE Chen","year":"2008","unstructured":"Chen\u00a0YE, Korbet\u00a0SM, Katz\u00a0RS, Schwartz\u00a0MM, Lewis\u00a0EJ, Collaborative Study Group (2008) Value of a\u00a0complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3:46\u201353","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1534_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13075-024-03292-y","volume":"26","author":"C Cheng","year":"2024","unstructured":"Cheng\u00a0C, Yang\u00a0H, Yang\u00a0C et\u00a0al (2024) LATS2 degradation promoted fibrosis damage and rescued by vitamin K3 in lupus nephritis. Arthritis Res Ther 26(1):64","journal-title":"Arthritis Res Ther"},{"key":"1534_CR14","doi-asserted-by":"publisher","first-page":"14353","DOI":"10.1038\/nrrheum.2015.159","volume":"12","author":"A Davidson","year":"2016","unstructured":"Davidson\u00a0A (2016) What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol 12:14353","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"1534_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Cheema\u00a0K et\u00a0al (2020) 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1534_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis\u00a0A, Tziolos\u00a0N, Bertsias\u00a0G, Boumpas\u00a0DT (2021) Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80(1):14\u201325","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1534_CR17","doi-asserted-by":"publisher","first-page":"e172569","DOI":"10.1172\/jci.insight.172569","volume":"9","author":"A Fava","year":"2024","unstructured":"Fava\u00a0A, Buyon\u00a0J, Magder\u00a0L et\u00a0al (2024) Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight 9(2):e172569","journal-title":"JCI Insight"},{"issue":"5","key":"1534_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.42023","volume":"74","author":"A Fava","year":"2022","unstructured":"Fava\u00a0A, Rao\u00a0DA, Mohan\u00a0C et\u00a0al (2022) Urine proteomics and renal single-cell transcriptomics implicate Interleukin-16 in lupus nephritis. Arthritis Rheumatol 74(5):829\u2013839","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1534_CR19","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3899\/jrheum.120537","volume":"39","author":"R Fischer-Betz","year":"2012","unstructured":"Fischer-Betz\u00a0R, Chehab\u00a0G, Sander\u00a0O et\u00a0al (2012) Renal outcome in patients with lupus nephritis using a\u00a0steroid-free regimen of monthly intravenous cyclophosphamide: a\u00a0prospective observational study. J\u00a0Rheumatol 39(11):2111\u20132117","journal-title":"J Rheumatol"},{"issue":"12","key":"1534_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et\u00a0al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N\u00a0Engl J Med 383(12):1117\u20131128","journal-title":"N Engl J Med"},{"issue":"11","key":"1534_CR21","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2215\/CJN.02520322","volume":"17","author":"R Furie","year":"2022","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et\u00a0al (2022) Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study. Clin J Am Soc Nephrol 17(11):1620\u20131630","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1534_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie\u00a0RA, Aroca\u00a0G, Cascino\u00a0MD et\u00a0al (2022) B\u2011cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a\u00a0randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81(1):100\u2013107","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"1534_CR23","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R et\u00a0al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383(15):1436\u20131446","journal-title":"N Engl J Med"},{"key":"1534_CR24","series-title":"bioRxiv [Preprint] 15:2024.01.14.575609","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.14.575609","volume-title":"Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis","author":"A Horisberger","year":"2024","unstructured":"Horisberger\u00a0A, Griffith\u00a0A, Keegan\u00a0J et\u00a0al (2024) Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv [Preprint] 15:2024.01.14.575609"},{"issue":"5","key":"1534_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/genes14051028","volume":"14","author":"SU Huang","year":"2023","unstructured":"Huang\u00a0SU, Kulatunge\u00a0O, O\u2019Sullivan\u00a0KM (2023) Deciphering the genetic code of autoimmune kidney diseases. Genes 14(5):1028","journal-title":"Genes"},{"key":"1534_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0961203319828822","volume":"28","author":"Y Huang","year":"2019","unstructured":"Huang\u00a0Y, Chen\u00a0L, Chen\u00a0K et\u00a0al (2019) Anti-enolase antibody combined with 2 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients. Lupus 28:365\u2013370","journal-title":"Lupus"},{"issue":"12","key":"1534_CR27","doi-asserted-by":"publisher","first-page":"102980","DOI":"10.1016\/j.autrev.2021.102980","volume":"20","author":"S Jamaly","year":"2021","unstructured":"Jamaly\u00a0S, Rakaee\u00a0M, Abdi\u00a0R, Tsokos\u00a0GC, Fenton\u00a0KA (2021) Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmun Rev 20(12):102980","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1534_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group (2024) KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int 105(1):S1\u2013S69","journal-title":"Kidney Int"},{"key":"1534_CR29","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/ndt\/gft201","volume":"28","author":"SM Korbet","year":"2013","unstructured":"Korbet\u00a0SM, Lewis\u00a0EJ, Collaborative Study Group (2013) Severe lupus nephritis: the predictive value of a\u00a0\u2265\u202f50\u202f% reduction in proteinuria at 6\u00a0months. Nephrol Dial Transplant 28:2313\u20132318","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1534_CR30","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3904\/kjim.2017.383","volume":"33","author":"SK Kwok","year":"2018","unstructured":"Kwok\u00a0SK, Tsokos\u00a0GC (2018) New insights into the role of renal resident cells in the pathogenesis of lupus nephritis. Korean J Intern Med 33(2):284\u2013289","journal-title":"Korean J Intern Med"},{"issue":"9","key":"1534_CR31","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/art.42516","volume":"75","author":"YC Kwon","year":"2023","unstructured":"Kwon\u00a0YC, Ha\u00a0E, Kwon\u00a0HH et\u00a0al (2023) Higher genetic risk loads confer more diverse manifestations and higher risk of lupus nephritis in systemic lupus erythematosus. Arthritis Rheumatol 75(9):1566\u20131572","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1534_CR32","doi-asserted-by":"publisher","first-page":"e0199003","DOI":"10.1371\/journal.pone.0199003","volume":"13","author":"CM Lanata","year":"2018","unstructured":"Lanata\u00a0CM, Nititham\u00a0J, Taylor\u00a0KE et\u00a0al (2018) Genetic contributions to lupus nephritis in a\u00a0multi-ethnic cohort of systemic lupus erythematous patients. PLoS ONE 13(6):e199003","journal-title":"PLoS ONE"},{"issue":"3","key":"1534_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41581-021-00510-7","volume":"18","author":"VA Luyckx","year":"2022","unstructured":"Luyckx\u00a0VA, Rule\u00a0AD, Tuttle\u00a0KR et\u00a0al (2022) Nephron overload as a\u00a0therapeutic target to maximize kidney lifespan. Nat Rev Nephrol 18(3):171\u2013183","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"1534_CR34","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen\u00a0A, M\u00fcller\u00a0F, Mougiakakos\u00a0D et\u00a0al (2022) Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"issue":"9","key":"1534_CR35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/0961203320932219","volume":"29","author":"A Mahajan","year":"2020","unstructured":"Mahajan\u00a0A, Amelio\u00a0J, Gairy\u00a0K et\u00a0al (2020) Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a\u00a0pragmatic review mapping disease severity and progression. Lupus 29(9):1011\u20131020","journal-title":"Lupus"},{"issue":"1","key":"1534_CR36","doi-asserted-by":"publisher","first-page":"e000584","DOI":"10.1136\/lupus-2021-000584","volume":"9","author":"S McDonald","year":"2022","unstructured":"MASTERPLANS Consortium, McDonald\u00a0S, Yiu\u00a0S, Su\u00a0L et\u00a0al (2022) Predictors of treatment response in a\u00a0lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Sci Med 9(1):e584","journal-title":"Lupus Sci Med"},{"issue":"7","key":"1534_CR37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00393-018-0496-4","volume":"77","author":"S Melderis","year":"2018","unstructured":"Melderis\u00a0S, Wiech\u00a0T, Iking-Konert\u00a0C, Steinmetz\u00a0OM (2018) Lupusnephritis. Z\u00a0Rheumatol 77(7):593\u2013608","journal-title":"Z Rheumatol"},{"issue":"1","key":"1534_CR38","doi-asserted-by":"publisher","first-page":"e000183","DOI":"10.1136\/lupus-2016-000183","volume":"3","author":"A Mok","year":"2016","unstructured":"Mok\u00a0A, Solomon\u00a0O, Nayak\u00a0RR et\u00a0al (2016) Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type\u00a01 interferon responses. Lupus Sci Med 3(1):e183","journal-title":"Lupus Sci Med"},{"key":"1534_CR39","doi-asserted-by":"publisher","first-page":"1105676","DOI":"10.3389\/fneph.2023.1105676","volume":"3","author":"E Morales","year":"2023","unstructured":"Morales\u00a0E, Sandino\u00a0J, Galindo\u00a0M (2023) Lupus nephropathy beyond immunosuppression: searching for nephro and cardioprotection. Front Nephrol 3:1105676","journal-title":"Front Nephrol"},{"issue":"8","key":"1534_CR40","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"D Mougiakakos","year":"2024","unstructured":"Mougiakakos\u00a0D, Bozec\u00a0A, Winkler\u00a0T, Kr\u00f6nke\u00a0G, Mackensen\u00a0A, Schett\u00a0G (2024) CD19 CAR T\u2011cell therapy in autoimmune disease\u2014a case series with follow-up. N\u00a0Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"issue":"1","key":"1534_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00393-022-01250-0","volume":"82","author":"J Mucke","year":"2023","unstructured":"Mucke\u00a0J, Schneider\u00a0M (2023) Lupusnephritis. Z\u00a0Rheumatol 82(1):40\u201352","journal-title":"Z Rheumatol"},{"issue":"8","key":"1534_CR42","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1136\/annrheumdis-2018-214379","volume":"78","author":"NI Panousis","year":"2019","unstructured":"Panousis\u00a0NI, Bertsias\u00a0GK, Ongen\u00a0H et\u00a0al (2019) Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis 78(8):1079\u20131089","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1534_CR43","doi-asserted-by":"publisher","first-page":"e000389","DOI":"10.1136\/lupus-2020-000389","volume":"7","author":"I Parodis","year":"2020","unstructured":"Parodis\u00a0I, Tamirou\u00a0F, Houssiau\u00a0FA (2020) Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med 7(1):e389","journal-title":"Lupus Sci Med"},{"issue":"4","key":"1534_CR44","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/ndt\/gfac304","volume":"38","author":"AA Perez-Arias","year":"2023","unstructured":"Perez-Arias\u00a0AA, M\u00e1rquez-Macedo\u00a0SE, Pena-Vizcarra\u00a0OR et\u00a0al (2023) The influence of repeated flares in response to therapy and prognosis in lupus nephritis. Nephrol Dial Transplant 38(4):884\u2013893","journal-title":"Nephrol Dial Transplant"},{"key":"1534_CR45","doi-asserted-by":"publisher","first-page":"808008","DOI":"10.3389\/fimmu.2021.808008","volume":"12","author":"OP Rekvig","year":"2022","unstructured":"Rekvig\u00a0OP (2022) The anti-DNA antibodies: their specificities for unique DNA structures and their unresolved clinical impact\u2014a system criticism and a\u00a0hypothesis. Front Immunol 12:808008","journal-title":"Front Immunol"},{"issue":"19","key":"1534_CR46","doi-asserted-by":"publisher","first-page":"14526","DOI":"10.3390\/ijms241914526","volume":"24","author":"Y Renaudineau","year":"2023","unstructured":"Renaudineau\u00a0Y, Brooks\u00a0W, Belliere\u00a0J (2023) Lupus nephritis risk factors and biomarkers: an update. Int J Mol Sci 24(19):14526","journal-title":"Int J Mol Sci"},{"key":"1534_CR47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/0961203319847275","volume":"28","author":"SE Reppe Moe","year":"2019","unstructured":"Reppe Moe\u00a0SE, Molberg \u00d8, Str\u00f8m\u00a0EH, Lerang\u00a0K (2019) Assessing the relative impact of lupus nephritis on mortality in a\u00a0population-based systemic lupus erythematosus cohort. Lupus 28:818\u2013825","journal-title":"Lupus"},{"issue":"10289","key":"1534_CR48","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Teng\u00a0YKO, Ginzler\u00a0EM et\u00a0al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase\u00a03\u00a0trial. Lancet 397(10289):2070\u20132080","journal-title":"Lancet"},{"issue":"1","key":"1534_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art.42657","volume":"76","author":"A Saxena","year":"2024","unstructured":"Saxena\u00a0A, Ginzler\u00a0EM, Gibson\u00a0K et\u00a0al (2024) Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase\u00a03 AURORA 2 clinical trial. Arthritis Rheumatol 76(1):59\u201367","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1534_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0961203317717083","volume":"27","author":"A Schwarting","year":"2018","unstructured":"Schwarting\u00a0A, Relle\u00a0M, Meineck\u00a0M, F\u00f6hr\u00a0B, Triantafyllias\u00a0K, Weinmann\u00a0A, Roth\u00a0W, Weinmann-Menke\u00a0J (2018) Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men. Lupus 27(2):243\u2013256","journal-title":"Lupus"},{"key":"1534_CR51","doi-asserted-by":"publisher","first-page":"108389","DOI":"10.1016\/j.clim.2020.108389","volume":"215","author":"K Song","year":"2020","unstructured":"Song\u00a0K, Liu\u00a0L, Zhang\u00a0X, Chen\u00a0X (2020) An update on genetic susceptibility in lupus nephritis. Clin Immunol 215:108389","journal-title":"Clin Immunol"},{"issue":"4","key":"1534_CR52","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s40620-020-00938-3","volume":"34","author":"FL Strufaldi","year":"2021","unstructured":"Strufaldi\u00a0FL, Menezes Neves\u00a0PDMM et\u00a0al (2021) Renal thrombotic microangiopathy associated to worse renal prognosis in Lupus Nephritis. J\u00a0Nephrol 34(4):1147\u20131156","journal-title":"J Nephrol"},{"issue":"1","key":"1534_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","volume":"56","author":"MW Tsang-A-Sjoe","year":"2017","unstructured":"Tsang-A-Sjoe\u00a0MW, Bultink\u00a0IE, Heslinga\u00a0M, Voskuyl\u00a0AE (2017) Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology 56(1):121\u2013128","journal-title":"Rheumatology"},{"issue":"6","key":"1534_CR54","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos\u00a0GC (2020) Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 21(6):605\u2013614","journal-title":"Nat Immunol"},{"issue":"4","key":"1534_CR55","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41581-023-00786-x","volume":"20","author":"GC Tsokos","year":"2024","unstructured":"Tsokos\u00a0GC, Boulougoura\u00a0A, Kasinath\u00a0V, Endo\u00a0Y, Abdi\u00a0R, Li\u00a0H (2024) The immunoregulatory roles of non-haematopoietic cells in the kidney. Nat Rev Nephrol 20(4):206\u2013217","journal-title":"Nat Rev Nephrol"},{"key":"1534_CR56","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/17512433.2022.2092470","volume":"15","author":"T van Gelder","year":"2022","unstructured":"van Gelder\u00a0T, Lerma\u00a0E, Engelke\u00a0K, Huizinga\u00a0RB (2022) Voclosporin: a\u00a0novel calcineurin inhibitor for the treatment of lupus nephritis. Expert Rev Clin Pharmacol 15:515\u2013529","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1534_CR57","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven\u00a0RF, Bertsias\u00a0G, Doria\u00a0A et\u00a0al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8(1):e538","journal-title":"Lupus Sci Med"},{"key":"1534_CR58","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41581-023-00732-x","volume":"19","author":"CG Vinuesa","year":"2023","unstructured":"Vinuesa\u00a0CG, Shen\u00a0N, Ware\u00a0T (2023) Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants. Nat Rev Nephrol 19:558\u2013572","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"1534_CR59","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/art.37940","volume":"65","author":"D Wofsy","year":"2013","unstructured":"Wofsy\u00a0D, Hillson\u00a0JL, Diamond\u00a0B (2013) Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum 65(6):1586\u20131591","journal-title":"Arthritis Rheum"},{"key":"1534_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","volume":"112","author":"M Zen","year":"2023","unstructured":"Zen\u00a0M, Salmaso\u00a0L, Barbiellini Amidei\u00a0C et\u00a0al (2023) Mortality and causes of death in systemic lupus erythematosus over the last decade: data from a\u00a0large population-based study. Eur J Intern Med 112:45\u201351","journal-title":"Eur J Intern Med"},{"issue":"10","key":"1534_CR61","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/ard-2023-224242","volume":"82","author":"XY Zhao","year":"2023","unstructured":"Zhao\u00a0XY, Li\u00a0SS, He\u00a0YX et\u00a0al (2023) SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis 82(10):1328\u20131340","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01534-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:26:35Z","timestamp":1723562795000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01534-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1534"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01534-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"18 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Schneider war als\u00a0Advisor und Referent f\u00fcr Astra-Zeneca, GSK und Otsuka t\u00e4tig. G.\u00a0Chehab erhielt Beraterhonorare von GSK, AstraZeneca, Otsuka und Alexion; die Klinik erh\u00e4lt eine Forschungsf\u00f6rderung von GSK und AstraZeneca. A.\u00a0Schwarting erh\u00e4lt Forschungsf\u00f6rderung von GSK, Novartis und Pfizer\u00a0und war Advisor und Referent f\u00fcr GSK t\u00e4tig.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}